XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
Study sponsor: Xenon Pharmaceuticals Inc. · XENE
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-16Actual
Enrollment · participants8Actual
Source updated2024-08-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.